La Haye
This article was originally published in The Tan Sheet
Executive Summary
Conducting Phase III clinical trials for an undisclosed dietary supplement ingredient to prevent macular degeneration and cataracts. Redmond, Washington-based La Haye said it plans to file an NDA for the product after the trials are completed, possibly within the next year. Testing began in 1989.